Is a Body Dysmorphic Disorder Screening Protocol Necessary in Cosmetic Dermatology?


The proliferation of aesthetic procedures in cosmetic dermatology, coupled with rising expectations for appearance, has brought several psychiatric disorders to the forefront. One such disorder, Body Dysmorphic Disorder (BDD), is characterized by the perception of a non-existent or insignificant bodily flaw as a major problem. The presence of this disorder in aesthetic procedures poses serious risks for both the patient and the practitioner. So, should aesthetic clinics be screened for BDD? Let's examine this question with scientific data.

What is BDD and Why Is It Important?
Body Dysmorphic Disorder (BDD) is characterized by unrealistic and excessively obsessive thoughts about one's appearance. According to the DSM-5, diagnostic criteria include exaggerated concerns about appearance, repetitive behaviors (such as mirror gazing, comparisons, excessive grooming), and impairment in social or occupational functioning. Furthermore, this disorder is often unnoticed by the individual and often emerges as a result of seeking to "solve the problem" by resorting to aesthetic procedures.

BDD coexists with many psychiatric disorders, such as depression, anxiety, and substance abuse. Furthermore, the risk of suicide in these individuals is significantly increased compared to the general population.

Why Is BDD Screening Necessary in Cosmetic Clinics?
Research shows that while the prevalence of BDD in the general population is 0.7% to 2.4%, this rate rises to over 14% in cosmetic dermatology patients. In other words, one in every seven people presenting with aesthetic concerns may be at risk for BDD.

Aesthetic procedures often exacerbate symptoms in these patients. The individual seeks treatment to improve their appearance, but regardless of the results, they often find new flaws or are dissatisfied with the procedure. This can lead to serious consequences for the practitioner, such as complaints, lawsuits, or even physical threats.

How Can BDD Screening Be Conducted?
In a pilot study conducted at eight aesthetic clinics in the United States, a multi-stage, confidential screening protocol was implemented. 734 new patients were screened over a 16-week period. Of these patients, 4.2% progressed to the second stage, and 29% (9 individuals) were found to be positive for BDD. Of these positive cases, 77.8% did not receive treatment and were referred to a mental health professional.

Screening was conducted as follows:

Confidential preliminary assessment: Questions were asked to distinguish healthy from unhealthy aesthetic motivations (e.g., responses such as "I want perfect symmetry" were considered red flags).

Secondary assessment: The modified COPS questionnaire was administered.

Tertiary assessment, if necessary: Counseling was provided, and the reasonableness of facial expressions and desired changes were assessed.

What Does This Mean for Practitioners?
The results of this study demonstrate that a confidential, multistage screening protocol is an effective method for identifying patients at risk for BDD. Practitioners protect not only the patients but also their own professional safety.

Strategies such as referring to a mental health professional, delaying treatment, or refusing treatment altogether are ethically sound and safer in the long run. Furthermore, this open communication environment with the patient encourages the individual to seek psychological support.

What are the Challenges Encountered in BDD Screening?

The main obstacles to BDD screening in aesthetic clinics are:

Lack of time and staff

Inadequate training in mental health

Lack of screening tools

Aesthetic patients manipulating tests out of fear of "rejection"

Practitioners' concern about missing patients

Despite these challenges, presenting the pre-screening as a list of personal goals and unconsciously screening the patient can reduce manipulation and yield more realistic results.

When and How Should BDD Screening Be Continued?
BDD isn't just detected during the initial consultation. Patients should also be carefully monitored after treatment. Red flags include:

Not seeing any changes after treatment

Finding new defects

Consistent dissatisfaction

Unrealistic demands

Such situations indicate the need for further counseling.

Conclusion: Why Should BDD Screening Be Standard Protocol?
A confidential, multistage screening protocol for body dysmorphic disorder in cosmetic dermatology practices is a valuable approach that considers not only the patient's psychological well-being but also the practitioner's ethical, legal, and professional safety.

Insight is as crucial as appearance in the world of aesthetics. Therefore, screening for BDD in aesthetic practices is not a luxury; it is a necessary safety measure to protect patient satisfaction, safety, and professional integrity.